Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-382
- Development stage
- Preclinical
- Lead developer
- University of Virginia
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
miR-382 is a tumor-suppressive microRNA being investigated as a therapeutic for glioblastoma. It acts as a master regulator by targeting and suppressing multiple oncogenic genes and pathways involved in tumor cell growth, survival, and invasion. In preclinical studies, miR-382 has demonstrated the ability to inhibit glioblastoma progression in vivo. To overcome the blood-brain barrier, researchers have developed delivery strategies using MRI-guided focused ultrasound combined with microbubbles to enhance the delivery of miR-382 to brain tumor sites. This approach aims to simultaneously inhibit multiple deregulated molecules in glioblastoma, potentially leading to more effective treatments than molecular monotherapies.
- Other names
- microRNA-382microRNA382microRNA 382miRNA-382miRNA382miRNA 382hsa-miR-382hsa-miR382hsa-miR 382
02
Targets
Homeodomain-interacting protein kinase 3 mRNA 3′ untranslated region (HIPK3 mRNA 3′UTR)ANXA3Kruppel-like factor 12 (KLF12) mRNA 3′ untranslated region (3′UTR)Vascular endothelial zinc finger 1 mRNA 3′-untranslated regionPTEN (Phosphatase and tensin homolog deleted on chromosome ten)Brain-derived neurotrophic factor messenger RNA 3' untranslated region (BDNF mRNA 3'UTR)
Beyond the preview
Go deeper on miR-382.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-382.